Insulin resistance (IR) plays a pivotal role in the pathogenesis of several dermatological diseases, including psoriasis, acne, acanthosis nigricans, and hidradenitis suppurativa (HS). These conditions are characterized by chronic inflammation, oxidative stress, and metabolic dysfunction, which are exacerbated by IR. This narrative review examines the emerging role of nutraceutical insulin-sensitizing agents (ISAs), including myo-inositol, alpha-lipoic acid, vitamin D, vitamin C, and folic acid, in managing IR-related dermatological disorders. A comprehensive literature search was conducted across Cochrane Library and MEDLINE (1965–May 2025), focusing on clinical trials involving nutraceutical ISAs in dermatological conditions associated with IR. Only human studies published in English were included. Evidence from randomized controlled trials (RCTs) and observational studies suggests that ISAs improve glycemic control, reduce oxidative stress, and modulate inflammatory pathways in IR-related dermatoses. Notably, myo-inositol combined with magnesium and folic acid has demonstrated significant reductions in acne severity, hirsutism, and quality-of-life impairments in women with polycystic ovary syndrome. Similar benefits have been observed in psoriasis and HS, though data remain limited. Nutraceutical ISAs offer a promising adjunctive approach for the management of IR-associated dermatological diseases, potentially addressing both metabolic dysfunction and skin inflammation. However, robust RCTs with long-term follow-up are needed to confirm these preliminary findings and to establish optimal treatment regimens.

Recently, there has been increasing interest in the complex function of insulin, not only in its familiar role as a blood glucose-regulating hormone but also as a growth factor and biological regulator. This publication reviews the literature related to insulin resistance (IR) as a causative and exacerbating element in functional urological disorders, including overactive bladder syndrome (OAB). Patients with OAB or similar disorders often present with seemingly unrelated medical issues, such as metabolic syndrome (MetS), fibromyalgia (FM), psoriatic arthritis (PsA), and polycystic ovary syndrome (PCOS). However, these conditions interact with one another and can result in complex clinical scenarios. The literature reviewed delineates a pathophysiological circuit among these disorders, which share the chronic inflammation and underlying oxidative stress caused by IR. Growing evidence from both animal model studies and randomized clinical trials indicates that certain molecules, such as myo-inositol (MI), magnesium (Mg²⁺), folic acid (FoA), vitamin C (Vc), ferulic acid (FA), and vitamin D (Vd), are effective in treating functional bladder disorders and other syndromes linked to IR. Their success is attributable first and foremost to their insulin-sensitizing actions and, therefore, to their antioxidant and anti-inflammatory properties. Moreover, these treatments are generally safe and well-tolerated, whether used alone or in combination with existing therapies. Therefore, administering these substances to patients with conditions in which IR is known to be a key etiologic factor holds scientific justification and represents a promising therapeutic approach with potential future applications.